Message #3 From:
Stock News Bot Date: September 8, 2006 04:00:00 AM
PKTX News ProtoKinetix AAGP(TM) Showcased at GECO(47)
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 8, 2006--ProtoKinetix, Inc. (OTCBB:PKTX) is pleased to report on the outstanding reception AAGP(TM) received from the scientific and pharmaceutical establishments attending the prestigious GECO(47) symposium. PKTX has been requested by several pharmaceutical companies to collaborate with them on a variety of exciting new applications for the family of AAGP(TM) molecules.
This presentation, delivered by Dr. Geraldine Deliencourt on behalf of INSA (France's Institute of Applied Sciences) and ProtoKinetix, was the first scientific peer review of the AAGP(TM) molecules. The Company and INSA were extremely gratified by the wide range of interest and absolute acceptance of this innovative technology. A copy of the presentation abstract is available on our website.
About ProtoKinetix:
ProtoKinetix, Inc. is a biotechnical company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP(TM)) for human and veterinary medicine, the biotechnology and cosmetic industries, and as a food additive. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world-recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future, and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
